Invasive Pulmonary Aspergillosis clinical trials at UCSF
1 research study open to eligible people
Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment
open to eligible people ages 18 years and up
This is a multicenter, open label, non-comparator, single arm study to evaluate the efficacy and safety of ibrexafungerp (SCY-078) in patients ≥ 18 years of age with a documented fungal disease that has been intolerant or refractory (rIFI) to Standard of Care (SoC) antifungal treatment.
San Francisco, California and other locations
Our lead scientists for Invasive Pulmonary Aspergillosis research studies include Peter Chin-Hong, MD.